Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment (relapsed/refractory multiple myeloma)
• People whose myeloma can be measured through at least one of the following: a specific protein in the blood (M-protein ≥ 0.5 g/dL), a specific protein in the urine over 24 hours, abnormal light chain levels in the blood, or a high proportion of myeloma cells in the bone marrow
• People who have already received at least one previous treatment for their myeloma
• People whose doctors are planning to treat them with a specific combination of three medicines: carfilzomib, daratumumab, and dexamethasone
• People who are reasonably active and able to carry out daily activities, as rated on a standard medical scale (ECOG score of 0, 1, or 2)
• People whose blood test results meet minimum levels for white blood cells, platelets, and haemoglobin (confirm specific values with trial site)
• People whose liver function blood tests are within an acceptable range
• People whose kidneys are working at a sufficient level (confirmed by a specific kidney function calculation)
• People whose heart is pumping at least 50% of its capacity, as measured by a heart scan
• People of childbearing potential who agree to use adequate contraception during the trial and for 6 months after the last dose of the study drug
• People who understand the nature of the trial and sign a written consent form before any study procedures begin

Who may not be able to join:

• People with a form of myeloma that does not produce measurable proteins (non-secretory myeloma), a condition called systemic light chain amyloidosis, or a single tumour form called plasmacytoma
• People who have had a bad reaction or intolerance to SX-682 or any of the other medicines used in this trial
• People whose myeloma did not respond to, or came back within 60 days of finishing, a previous treatment with carfilzomib
• People whose myeloma did not respond to, or came back within 60 days of finishing, a previous treatment with daratumumab
• People currently taking certain other medications that strongly affect how the body processes drugs, or that are known to affect heart rhythm, unless those medications are considered absolutely essential with no alternative available (confirm with trial site)
• People whose heart electrical activity test (ECG) shows a specific measurement (QTc interval) above 470 milliseconds, or people born with a condition called long QT syndrome
• People who have had a heart bypass, angioplasty, a stent, a heart attack, chest pain (angina), or heart failure within the last 6 months
• People with serious uncontrolled health conditions, including active infections, unstable heart conditions, severe heart failure (Class III or IV), or mental health or personal circumstances that may make it difficult to follow the study requirements
• People with a history of hepatitis B, hepatitis C, or HIV
• People with a known active tuberculosis infection
• People who are pregnant or breastfeeding
• People who are unwilling or unable to follow the requirements of the study
• People whom the trial doctor considers unsuitable to receive the study drug for any reason

Important: Always verify eligibility with the trial site directly before applying.